Literature DB >> 15469940

Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215.

Qiyuan Liu1, Satoshi Kaneko, Lin Yang, Richard I Feldman, Santo V Nicosia, Jiandong Chen, Jin Q Cheng.   

Abstract

The tumor suppressor p53 is important in the decision to either arrest cell cycle progression or induce apoptosis in response to a variety of stimuli. p53 posttranslational modifications and association with other proteins have been implicated in the regulation of its stability and transactivation activity. Here we show that p53 is phosphorylated by the mitotic kinase Aurora-A at serine 215. Unlike most identified phosphorylation sites of p53 that positively associate with p53 function (Brooks, C. L., and Gu, W. (2003) Curr. Opin. Cell Biol. 15, 164-171), the phosphorylation of p53 by Aurora-A at Ser-215 abrogates p53 DNA binding and transactivation activity. Downstream target genes of p53, such as p21Cip/WAF1 and PTEN, were inhibited by Aurora-A in a Ser-215 phosphorylation-dependent manner (i.e. phosphomimic p53-S215D lost and non-phosphorylatable p53-S215A retained normal p53 function). As a result, Aurora-A overrides the apoptosis and cell cycle arrest induced by cisplatin and gamma-irradiation, respectively. However, the effect of Aurora-A on p53 DNA binding and transactivation activity was not affected by phosphorylation of Ser-315, a recently identified Aurora-A phosphorylation site of p53 (Katayama, H., Sasai, K., Kawai, H., Yuan, Z. M., Bondaruk, J., Suzuki, F., Fujii, S., Arlinghaus, R. B., Czerniak, B. A., and Sen, S. (2004) Nat. Genet. 36, 55-62). Our data indicate that phosphorylation of p53 at Ser-215 by Aurora-A is a major mechanism to inactivate p53 and can provide a molecular insight for Aurora-A function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15469940     DOI: 10.1074/jbc.M406802200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  117 in total

1.  Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells.

Authors:  Anna E Vilgelm; Jeff S Pawlikowski; Yan Liu; Oriana E Hawkins; Tyler A Davis; Jessica Smith; Kevin P Weller; Linda W Horton; Colt M McClain; Gregory D Ayers; David C Turner; David C Essaka; Clinton F Stewart; Jeffrey A Sosman; Mark C Kelley; Jeffrey A Ecsedy; Jeffrey N Johnston; Ann Richmond
Journal:  Cancer Res       Date:  2014-11-14       Impact factor: 12.701

2.  Aurora A mediates cross-talk between N- and C-terminal post-translational modifications of p53.

Authors:  Lorna Jane Warnock; Sally Anne Raines; Jo Milner
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

3.  Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2.

Authors:  Gong Yang; Bin Chang; Fan Yang; Xiaoqing Guo; Kathy Qi Cai; Xue Sherry Xiao; Huamin Wang; Subrata Sen; Mien-Chie Hung; Gordon B Mills; Sandy Chang; Asha S Multani; Imelda Mercado-Uribe; Jinsong Liu
Journal:  Clin Cancer Res       Date:  2010-04-27       Impact factor: 12.531

Review 4.  Aurora kinase inhibitors as anticancer molecules.

Authors:  Hiroshi Katayama; Subrata Sen
Journal:  Biochim Biophys Acta       Date:  2010-09-20

5.  Suppression of Aurora-A oncogenic potential by c-Myc downregulation.

Authors:  Shangbin Yang; Shun He; Xiaobo Zhou; Mei Liu; Hongxia Zhu; Yihua Wang; Wei Zhang; Shuang Yan; Lanping Quan; Jingfeng Bai; Ningzhi Xu
Journal:  Exp Mol Med       Date:  2010-11-30       Impact factor: 8.718

6.  Identification of Myb-binding protein 1A (MYBBP1A) as a novel substrate for aurora B kinase.

Authors:  Claudia Perrera; Riccardo Colombo; Barbara Valsasina; Patrizia Carpinelli; Sonia Troiani; Michele Modugno; Laura Gianellini; Paolo Cappella; Antonella Isacchi; Jurgen Moll; Luisa Rusconi
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

7.  Extensive post-translational modification of active and inactivated forms of endogenous p53.

Authors:  Caroline J DeHart; Jasdave S Chahal; S J Flint; David H Perlman
Journal:  Mol Cell Proteomics       Date:  2013-09-20       Impact factor: 5.911

Review 8.  The Unexpected Roles of Aurora A Kinase in Gliobastoma Recurrences.

Authors:  Estelle Willems; Arnaud Lombard; Matthias Dedobbeleer; Nicolas Goffart; Bernard Rogister
Journal:  Target Oncol       Date:  2017-02       Impact factor: 4.493

9.  Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice.

Authors:  Steven L Warner; Ruben M Muñoz; David J Bearss; Paul Grippo; Haiyong Han; Daniel D Von Hoff
Journal:  Pancreas       Date:  2008-10       Impact factor: 3.327

10.  Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer.

Authors:  Warapen Treekitkarnmongkol; Hiroshi Katayama; Kazuharu Kai; Kaori Sasai; Jennifer Carter Jones; Jing Wang; Li Shen; Aysegul A Sahin; Mihai Gagea; Naoto T Ueno; Chad J Creighton; Subrata Sen
Journal:  Carcinogenesis       Date:  2016-09-13       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.